Company Profile For OrthogenRx

--(BUSINESS WIRE)--OrthogenRx Inc. is a late stage product development company focused on the commercialization of Class III orthopedic medical devices. The business model obtains exclusive licenses for products presently sold/manufactured ex-U.S. that are identical to those approved in the U.S., and then seeks FDA product approval. The initial focus is on a market with 2014 sales of $924MM. The first product, GenVisc 850 (sodium hyaluronate), was approved by the FDA for the treatment of osteoarthritis knee pain in September 2015, just 20 months and $1.4MM following Seed investment compared to the industry standard of 6-8 yrs and $70MM - $100MM. OrthogenRx will launch their first product through a Contract Sales Organization, with sales projected in early 2016. An established customer base is targeted with very favorable reimbursements for physicians over the branded product. With a promising product portfolio in development, projected sales are >$200MM by 2019. Internal regulatory expertise, a promising pipeline and novel go to market strategy is disruptive and could create a new segment of the medical device industry, similar to generic drugs and biosimilars. Senior management has decades of experience in all phases of commercialization with a documented history of success. A $7.5MM Series A funding is sought to support product launch through a Contract Sales Organization (CSO), purchase inventory and support our product development. Projected ROI to investors is estimated to be 15-20 fold multiples within 2-4 years, most likely through acquisition.

jobspost your resume

Help employers find you! Check out all the and .